Hansa Biopharma announces $70 million
-
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform
"Proceeds will be mainly utilized to:
Further strengthen the Company's position in kidney transplantation through the continued support of ongoing European commercial launch activities for Idefirix (imlifidase) and execution of the U.S. ConfIdeS trial of imlifidase, which is expected to support a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway in the first half of 2024. In addition, Hansa will advance the global Phase 3 clinical trial of imlifidase in anti-GBM antibody disease and ongoing clinical programs in other indications"
"“This transaction, which extends our cash runway through 2024, helps bolster our ability to invest in the continued development of our unique antibody-cleaving enzyme technology platform across multiple therapeutic areas,” said Donato Spota, Chief Financial Officer of Hansa Biopharma."
-
Dejligt vi slipper for mere udvanding/emissioner og istedetfor afregner med (1 cifret) royalty af salget....Burde give et pænt løft imorgen, men lad so nu se
$70 million in financingUnder the terms of the agreement, NovaQuest will provide Hansa with $70 million within 15 business days from the execution of the agreement. In return, Hansa will make quarterly mid single-digit royalty payments to NovaQuest on future worldwide annual net sales of imlifidase, commencing upon approval by the FDA of imlifidase in kidney transplantation or anti-GBM. In addition, Hansa will make certain milestone payments to NovaQuest upon FDA approval of imlifidase in kidney transplantation or anti-GBM. Total payments by Hansa to NovaQuest are capped.at $140 million. The agreement also provides for time-based catch-up payments within the payment cap if specified payment amounts have not been received by NovaQuest by specified dates, with the last potential catch-up payment due on December 31, 2028. In addition, the transaction includes customary diligence, governance, and information obligations as well as non-financial covenants. Hansa and NovaQuest have also entered into a security agreement to provide NovaQuest a customary security interest in and lien upon right, title and interest in certain of Hansa's assets and IP.
-
"Investment Criteria
NovaQuest works directly with companies to help make their R&D pipelines a reality for patients and caregivers around the globe. We look to partner with seasoned teams of pharma operators focused on long term value creation, which have promising late-stage assets and unmet capital needs"
-
Hansa Biopharma half year report 2022
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-half-year-report-2022,c3602880
• Continued solid sales in Q2
• Positive NICE recommendation obtained
• Completed enrollment in imlifidase Phase 2 program in AMR
• Peter Nicklin elected as new Chairman of the Board of Directors
-
-
Aktien er pænt shortet, så mon ikke nogen af dem begynder at lukke deres positioner. Mange shortere har nok "spillet" på mere udvanding og emissioner til MEGET lave priser, så den her finansiering "snyder" dem nok lidt.
-
Amerikanerne køber pænt ind idag....
Goldman Sachs Bank Europe SE +42.615
J.P. Morgan AG +36.086
Morgan Stanley Europe SE +12.321
BofA Securities Europe SA +8.078 -
Husk CC idag kl. 14:00.
The webcast will be available on:
-
Hansa Biopharma Q2; Idefirix sales progress and secured funding to end 2024
-
Hansa Biopharma AB (publ) (HNSBF) CEO Søren Tulstrup on Q2 2022 Results - Earnings Call Transcript
Company Participants
Søren Tulstrup - CEO
Donato Spota - CFO
Conference Call Participants
Dominic Rose - Intron Health Research
Douglas Tsao - H.C. Wainwright
Zoe Karamanoli - RBC Capital Markets
Adam Karlsson - ABG Sundal Collier
Jacob Mekhael - Kempen & Co.
Johan Unnerus - Redeye
Christopher Uhde - SEB
-
Den finansiering tog godt nok røven på shorterne
Shorterne havde nok sat næsen op efter finansiering gennem emission og billige aktier til omkring kurs 30-40....Men de fik travlt med at lukke shorts idag Tænker ikke kurs 100 er langt væk nu. Vi får se spændende selskab. -
SEB OPJUSTERER KURSMÅL PÅ HANSA BIOPHARMA
"Emerging from the wilderness
With its cash position secured into H2/24 and sales of Idefirix now becoming more consistent, we are increasingly confident that Hansa has emerged from the heart of the wilderness. Clearly, there is work to be done on the salesfront, but with reimbursements continuing to develop positively, we believe there is rising clarity on near-term sales evolution. With potential triggersremaining in H2, we expect Hansa to outperform the market. Buy.Building sales momentum and controlling the burn rate
Although not as high as Q1, Q2 sales of Idefirix reached SEK 19.5m, the next-bestquarter to date. Hansa continues to be disciplined in its cash burn rate at SEK -135.6m, with SG&A 18% below our estimates. Encouragingly, R&D costs were 16% higher than we forecast, implying healthy development activity. Set to gain momentum in H2/22 with upside from clinical dataIn terms of the outlook for the rest of 2022, France, Switzerland, and the UK are likely to contribute meaningfully to top-line growth in H2, and centres that had transplanted their first patients are likely to start using Idefirix again, given that results appear to be consistent with published experience. Patients will not bring recurring revenue, but centres will, and this should only accelerate as the year comes to a close. The clinical programme remains on track, with the phase 2 AMR
trial due to read out in H2/22. We note a degree of optionality in that thisrandomised trial feasibly has the potential to be pivotal should the data be sufficiently compelling.Lift target price to SEK 260 (230)
We raise our Idefirix estimates on the back of the sales beat, and update ourmodel to reflect the financing from NovaQuest. Accordingly, we raise our SOTP-rNPV-based target price to SEK 260 (230) and reiterate our Buy rating". -
CARNEGIE OPJUSTER KURSMÅL TIL SEK 121.
ERIK PENSER BANK TIL SEK 240-250
RBC TIL SEK 171
-
Penser Access: Snygg finansieringslösning - Hansa Biopharma
https://docs.penser.se/a/2943/HNSA20220720.pdf
"Efter rapporten och den annonserade kapitalanskaffningen upprepar vi vårt fundamentala motiverade värde om 240-250 kronor per aktie. Vi bedömer att närmsta 12 månader kommer erbjuda flertalet triggers som kan minska värdegapet till vårt motiverade värde."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind